Published in J Immunol on August 01, 1989
Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A (1993) 10.82
Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest (1991) 2.18
Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest (1990) 2.02
Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action. J Exp Med (1990) 1.51
Role of transforming growth factor-beta in hematologic malignancies. Blood (2006) 1.41
Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells. Proc Natl Acad Sci U S A (1993) 1.09
Stimulation of granulopoiesis by transforming growth factor beta: synergy with granulocyte/macrophage-colony-stimulating factor. Proc Natl Acad Sci U S A (1991) 0.96
Transforming growth factor beta 1 is an inducer of erythroid differentiation. J Exp Med (1994) 0.94
Mechanisms of TGFbeta inhibition of LUNG endodermal morphogenesis: the role of TbetaRII, Smads, Nkx2.1 and Pten. Dev Biol (2008) 0.93
Recombinant transforming growth factor beta 1 and beta 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J Exp Med (1994) 0.92
Establishment and regulation of the HSC niche: Roles of osteoblastic and vascular compartments. Birth Defects Res C Embryo Today (2010) 0.84
Downregulation of Prdm16 mRNA is a specific antileukemic mechanism during HOXB4-mediated HSC expansion in vivo. Blood (2014) 0.83
A quantitative trait locus on chromosome 4 affects cycling of hematopoietic stem and progenitor cells through regulation of TGF-beta 2 responsiveness. J Immunol (2008) 0.83
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (1976) 15.73
Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci U S A (1978) 9.59
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Functional and morphologic characterization of human T cells continuously grown in vitro. J Immunol (1977) 6.30
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol (1991) 5.02
Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med (1984) 4.73
Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology (1981) 4.68
Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia. Nature (1981) 4.38
Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells. J Immunol (1981) 4.27
Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes. Proc Natl Acad Sci U S A (1981) 4.24
Long-term culture of human antigen-specific cytotoxic T-cell lines. J Exp Med (1978) 3.80
Risk factors associated with failure to receive vaccinations. Pediatrics (1979) 3.44
The fine specificity of antigen and Ia determinant recognition by T cell hybridoma clones specific for pigeon cytochrome c. Cell (1982) 3.38
Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med (1981) 3.30
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18
T-cell growth factor-mediated T-cell proliferation. Ann N Y Acad Sci (1979) 3.16
T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor. Proc Natl Acad Sci U S A (1980) 2.89
Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. J Biol Chem (1998) 2.80
Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethylsulfoxide. J Exp Med (1979) 2.80
Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem (1996) 2.78
Immunological properties of a type C retrovirus isolated from cultured human T-lymphoma cells and comparison to other mammalian retroviruses. J Virol (1981) 2.72
Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro. J Immunol (1996) 2.62
Death in the AIDS patient: role of cytomegalovirus. N Engl J Med (1983) 2.61
Human T-lymphocyte growth factor: regulation of growth and function of T lymphocytes. Blood (1981) 2.58
Detection of the human T cell lymphoma virus p19 in cells of some patients with cutaneous T cell lymphoma and leukemia using a monoclonal antibody. J Exp Med (1981) 2.47
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med (2001) 2.37
Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest (1995) 2.29
Absence of the Lyt-2-,L3T4+ lineage of T cells in mice treated neonatally with anti-I-A correlates with absence of intrathymic I-A-bearing antigen-presenting cell function. J Exp Med (1985) 2.27
Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med (1985) 2.18
Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun (1997) 2.14
Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function. J Exp Med (1985) 2.14
T-cell growth factor and the culture of cloned functional T cells. Adv Immunol (1981) 2.09
Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest (1998) 2.06
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping. J Virol (1989) 2.00
Natural antibodies to the human T cell lymphoma virus in patients with cutaneous T cell lymphomas. J Exp Med (1981) 1.84
Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem (1995) 1.80
Identification of distinct predominant epitopes recognized by myoglobin-specific T cells under the control of different Ir genes and characterization of representative T cell clones. J Immunol (1984) 1.75
Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci U S A (1999) 1.72
Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood (2001) 1.71
IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol (1999) 1.71
Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol (1998) 1.70
Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol (1996) 1.70
Peripheral clonal elimination of functional T cells. Science (1990) 1.69
p53 mutation is associated with progression in follicular lymphomas. Blood (1993) 1.69
Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ (1994) 1.68
Functional and molecular characteristics of T-cell growth factor. Mol Immunol (1980) 1.66
Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood (1992) 1.66
Murine syngeneic mixed lymphocyte response. I. Target antigens are self Ia molecules. J Exp Med (1981) 1.65
Clonal analysis of the major histocompatibility complex restriction and the fine specificity of antigen recognition in the T cell proliferative response to cytochrome C. J Immunol (1983) 1.63
The relationship between immune interferon production and proliferation in antigen-specific, MHC-restricted T cell lines and clones. J Immunol (1983) 1.61
Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol (1999) 1.61
Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest (1998) 1.61
Isolation of HTLV-transformed B-lymphocyte clone from a patient with HTLV-associated adult T-cell leukaemia. Nature (1984) 1.58
In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur J Immunol (2000) 1.57
The control of chemotherapy-induced emesis. Ann Intern Med (1981) 1.55
Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol (1986) 1.55
Immortalized hemopoietic cells with stem cell properties. Immunity (1994) 1.55
Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol (1985) 1.55
Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst (1993) 1.54
Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol (1991) 1.53
T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest (1996) 1.53
Kappa B site-dependent activation of the interleukin-2 receptor alpha-chain gene promoter by human c-Rel. Mol Cell Biol (1992) 1.52
Small noncleaved cell lymphoma associated with florid epithelioid granulomatous response. A clinicopathologic study of seven patients. Am J Surg Pathol (1993) 1.51
Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action. J Exp Med (1990) 1.51
Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer (1982) 1.50
Gene complementation. Neither Ir-GLphi gene need be present in the proliferative T cell to generate an immune response to Poly(Glu55Lys36Phe9)n. J Exp Med (1980) 1.49
Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent downregulation of IFN-gamma production. Mol Cell Biol (1998) 1.48
Growth hormone as an immunomodulating therapeutic agent. Immunol Today (2000) 1.48
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J Clin Oncol (1993) 1.46
Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab (1998) 1.46
Hodgkin's disease following non-Hodgkin's lymphoma. A clinicopathologic and immunophenotypic study of nine cases. Am J Surg Pathol (1993) 1.45
Nitric oxide scavenging by hemoglobin or nitric oxide synthase inhibition by N-nitro-L-arginine induces cortical spreading ischemia when K+ is increased in the subarachnoid space. J Cereb Blood Flow Metab (1998) 1.44
Lymphocytic lymphoma of intermediate differentiation--mantle zone lymphoma: a distinct subtype of B-cell lymphoma. Hum Pathol (1987) 1.44
Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood (1994) 1.43
Specific release of neutrophillic- and eosinophilic-stimulating factors from sensitized lymphocytes. Blood (1976) 1.43
Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity. Proc Natl Acad Sci U S A (1986) 1.43
Haemodilution with dextran 40 and hydroxyethyl starch and its effect on cerebral microcirculation. J Neurol (1989) 1.43
Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver. J Exp Med (1984) 1.41
Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer (1990) 1.40
Administration of recombinant human IL-7 to mice alters the composition of B-lineage cells and T cell subsets, enhances T cell function, and induces regression of established metastases. J Immunol (1994) 1.39
Bcl-2 and Bcl-X(L) block thapsigargin-induced nitric oxide generation, c-Jun NH(2)-terminal kinase activity, and apoptosis. Mol Cell Biol (1999) 1.39
You say tomato and I say tomahto: getting a handle on pronouncing apoptosis. J Natl Cancer Inst (1997) 1.39
A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma. Cancer Invest (1998) 1.39
Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. J Natl Cancer Inst (1995) 1.39
What's the deal with follicular lymphomas? J Clin Oncol (1993) 1.39
Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells. J Immunol (1986) 1.37
Relationships between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ (1992) 1.37
Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil. J Natl Cancer Inst (1995) 1.37